Real-World Evidence of Omnipod ® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes
Authors' conclusion
These glycemic outcomes from a large and diverse sample of nearly 70,000 children and adults demonstrate effective use of the Omnipod 5 System under real-world conditions.
Study context
- Population
- US Omnipod 5 System users aged ≥2 years with T1D and sufficient data (≥90 days of data; ≥75% of days with ≥220 CGM readings/day), Insulet device and person-reported datasets as of July 2023
- Participants
- 69,902 participants
- Exposure
- Average glucose targets of 110, 120 and 130-150 mg/dL
- 110 mg/dLn = 37,640
- Outcome
- Median time in range (TIR) (70-180 mg/dL)
Methodological detailsreal-world, subgroup analyses, stratification by baseline characteristics
- Real-world
- Subgroup analyses
- Stratification by baseline characteristics
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Median
| Outcome | Children and adolescents (2-17 years) | Adults (≥18 years) |
|---|---|---|
| Median TIR, average glucose target 110 mg/dL, by age | 65.0% | 69.9% |
Subgroups transitioning from Omnipod DASH or MDI, and Medicaid/Medicare users
- Favorable glycemic outcomes among these groups
Original publication
Real-World Evidence of Omnipod ® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technol Ther. Published 16 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →